Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 4 of 162 for:    Brain and Spinal Tumors

A Phase I/II Study of the Photon Radiosurgery System

This study has been completed.
Photoelectron Corporation
Information provided by (Responsible Party):
Stewart Goldman, Ann & Robert H Lurie Children's Hospital of Chicago Identifier:
First received: September 12, 2005
Last updated: February 27, 2015
Last verified: February 2015

The standard treatment for children with brain tumors is surgical removal of the tumor followed by radiation to the brain and chemotherapy (medicines) given to shrink any remaining tumor or to prevent tumor from growing back. There are very few treatment options available for children whose brain tumor grows back after receiving radiation treatment. There is a greater risk of complications and side effects when the brain is repeatedly treated with external radiation. The side effects of repeat radiation treatment are dependent on the amount of the brain that is radiated. Radiation given with PRS during surgery is focused to the specific area of the brain where the tumor is located. Therefore, the area of the brain affected by the radiation is smaller. It is hoped that this targeted radiation will lessen the side effects to the normal brain that is not affected by the tumor. It is also hoped that a lower occurrence of side effects will increase the quality of life of children with brain tumors.

The optimal dose of targeted radiation is not known. Therefore, increasing doses will be given to treat different patients, starting with the lowest possible dose. The amount of radiation to be given will depend on whether or not your child received prior radiation therapy and where the tumor is located. The groups of patients will first be divided into 2 groups: Group A, who are those who received radiation as part of their prior treatment, and Group B, who are those who did not receive any radiation treatment. Each group will be then divided again into 2 groups depending on the location of the tumor. In each group, if the lowest dose is well-tolerated with only minimal side effects by 3 patients, then the next higher dose will be given to the next 3 patients.

The purposes of this research are:

  • To evaluate the potential side effects of a single high dose of x-rays using the Photon Radiosurgery System (PRS) given to a small area of the brain.
  • To determine the maximum dose of targeted radiation that can be safely given to brain tumors with the fewest side effects.
  • To see how well this treatment works for children with recurrent brain tumors and newly-diagnosed glioblastoma multiforme.

Condition Intervention Phase
Brain Tumor, Recurrent
Glioblastoma Multiforme
Procedure: Photon Radiosurgery System (Intrabeam)
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Reirradiation for Recurrent Pediatric Brain and Spinal Cord Tumors and Primary Glioblastoma Multiforme Using the Photon Radiosurgery System

Resource links provided by NLM:

Further study details as provided by Ann & Robert H Lurie Children's Hospital of Chicago:

Primary Outcome Measures:
  • To determine the maximum tolerated dose of radiation that can be delivered using the Photon Radiosurgery System (PRS) in children with radiation recurrent brain tumors. [ Time Frame: End of study ]
  • To determine the maximum tolerated dose of radiation that can be delivered with a combination of external irradiation and radiosurgery using PRS in children with glioblastoma multiforme and children with recurrent ependymoma [ Time Frame: End of study ]
  • To determine the tumor response following reirradiation with PRS. [ Time Frame: End of study ]

Secondary Outcome Measures:
  • To determine the quality of life of children following irradiation with PRS. [ Time Frame: End of study ]
  • To study gene expression in tumors before and after irradiation with PRS [ Time Frame: End of study ]

Estimated Enrollment: 35
Study Start Date: May 2001
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Photon Radiosurgery System (Intrabeam)
    In this study we had intended to perform a similar dose escalation study with doses ranging from 10-19 Gy, 10-16 Gy and 10 - 14 Gy for tumors < 20 mm, 21-25 mm and 26-40 mm respectively
  Show Detailed Description


Ages Eligible for Study:   2 Years to 32 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All patients must be between 2 and 32 yrs. of age. Patients who are pregnant or lactating will not be included in this study.
  • Patients must have an estimated survival time of > 3 months, and a Karnofsky performance status of > 50% or and ECOG performance status of 0-2.
  • Patient must have radiographic imaging evidence of tumor recurrence except for glioblastoma multiforme.
  • The recurrent tumor prior to irradiation with PRS must be < 4 cm.
  • All patients must be > 3 weeks from cytotoxic chemotherapy, except if patient received < 1 week of non-myelotoxic chemotherapy. In that case, patient may be enrolled with permission of the principal investigator.
  • All patients must be > 6 weeks from high dose chemotherapy with stem cell rescue.
  • All patients must be > 3 weeks from prior radiation therapy.
  • Patients with a history of prior irradiation will be included.
  • Informed consent must be obtained prior to registration on the study.

Tumor Sites:

  • Brain
  • Spinal Cord

Tumor Types:

  • Recurrent Medulloblastoma
  • Recurrent Ependymoma (recurrence regardless of primary treatment)
  • Recurrent Glioma
  • Glioblastoma Multiforme
  • Recurrent Craniopharyngioma
  • Recurrent PNET (Primitive Neuroectodermal tumor)
  • Recurrent Meningioma
  • Recurrent Pineoblastoma

Tumor Size:

  • < 4 cm in maximum diameter
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00179907

United States, Illinois
Children's Memorial Hospital
Chicago, Illinois, United States, 60614
Sponsors and Collaborators
Ann & Robert H Lurie Children's Hospital of Chicago
Photoelectron Corporation
Principal Investigator: Tadanori Tomita, MD Ann & Robert H Lurie Children's Hospital of Chicago
Principal Investigator: John A. Kalapurakal, MD Northwestern Memorial Hospital
  More Information

Responsible Party: Stewart Goldman, Attending, Ann & Robert H Lurie Children's Hospital of Chicago Identifier: NCT00179907     History of Changes
Other Study ID Numbers: CNS 0201
Study First Received: September 12, 2005
Last Updated: February 27, 2015

Additional relevant MeSH terms:
Brain Neoplasms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms by Site
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases processed this record on April 28, 2017